首页> 外文期刊>European journal of pharmaceutical sciences >Tanshinone IIA - loaded pellets developed for angina chronotherapy: Deconvolution-based formulation design and optimization, pharmacokinetic and pharmacodynamic evaluation
【24h】

Tanshinone IIA - loaded pellets developed for angina chronotherapy: Deconvolution-based formulation design and optimization, pharmacokinetic and pharmacodynamic evaluation

机译:丹参酮IIA载药小球,用于心绞痛计时疗法:基于反卷积的配方设计和优化,药代动力学和药效动力学评估

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

This paper put forward a deconvolution-based method for designing and optimizing tanshinone IIA sustained-release pellets (TA-SRPs) with improved efficacy in the treatment of variant angina. TA-SRPs were prepared by coating TA ternary solid dispersion immediate-release pellets (TA-tSD-IRPs) with the blends of polyvinyl acetate (PVAc) and polyvinyl alcohol-polyethylene glycol (PVA-PEG) using fluidized bed technology. The plasma concentration-time curve of TA-tSD-IRPs following oral administration as a weight function was investigated in New Zealand white rabbits. The predicted/expected plasma concentration-time curve of TA-SRPs as a response function was simulated according to the circadian rhythm of variant angina during 24 h based on chronotherapy theory. The desired drug release profile of TA-SRPs was obtained via the point-area deconvolution procedure using the weight function and response function, and used for formulation optimization of TA-SRPs. The coating formulation of TA-SRPs was optimized as 70:30 (w/w) PVAc/PVA-PEG with 5% (w/w) coating weight due to in vitro drug release profile of these TA-SRPs was similar to the desired release profile (similarity factor f(2) = 64.90). Pharmacokinetic studies of these optimized TA-SRPs validated that their actual plasma concentration-time curve possessed a basically consistent trend with the predicted plasma concentration-time curve and the absolute percent errors (%PE) of concentrations in 8-12 h were less than 10%. Pharmacodynamic studies further demonstrated that these TA-SRPs had stable and improved efficacy with almost simultaneous drug concentration-efficacy. In conclusion, deconvolution could be employed in the development of TA-SRPs for angina chronotherapy with simultaneous drug efficacy and reduced design blindness and complexity. (C) 2015 Elsevier B.V. All rights reserved.
机译:本文提出了一种基于反卷积的丹参酮IIA缓释微丸(TA-SRPs)设计和优化方法,该方法可改善变异型心绞痛的疗效。通过使用流化床技术,用聚乙酸乙烯酯(PVAc)和聚乙烯醇-聚乙二醇(PVA-PEG)的共混物包裹TA三元固体分散体速释微丸(TA-tSD-IRPs),制备TA-SRP。在新西兰白兔中研究了口服给药后TA-tSD-IRPs的血浆浓度-时间曲线作为体重函数。根据变时性心绞痛24小时的昼夜节律,根据计时疗法理论模拟了TA-SRPs作为反应函数的预测/预期血浆浓度-时间曲线。通过使用重量函数和响应函数的点面积反卷积过程获得TA-SRPs的所需药物释放曲线,并将其用于TA-SRPs的配方优化。由于这些TA-SRPs的体外药物释放曲线与TA-SRPs的涂料配方优化为70:30(w / w)PVAc / PVA-PEG,涂层重量为5%(w / w)释放配置文件(相似因子f(2)= 64.90)。这些优化的TA-SRP的药代动力学研究证实,它们的实际血浆浓度-时间曲线与预测的血浆浓度-时间曲线具有基本一致的趋势,并且8-12 h浓度的绝对百分比误差(%PE)小于10 %。药效学研究进一步表明,这些TA-SRP具有稳定且提高的功效,几乎同时具有药物浓度-功效。总之,反卷积可用于心绞痛年代疗法的TA-SRPs的开发中,同时具有药物功效,并减少了设计盲目性和复杂性。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号